IDbyDNA Announces Agreement with ZeptoMetrix to Support Quality Control Products
SAN FRANCISCO & SALT LAKE CITY--(BUSINESS WIRE)--May 14, 2019--
IDbyDNA, a metagenomics technology company setting a new standard for the identification and understanding of microorganisms and their role in human health, today announced a commercial agreement with ZeptoMetrix, a world leading laboratory quality control (QC) and reference materials supplier. IDbyDNA will use the Explify ® metagenomics technology platform to analyze such materials provided by ZeptoMetrix to ensure the accurate identification, molecular typing, and biological purity of viral reference strains, bacterial isolates, and other materials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005081/en/
“ZeptoMetrix is the preferred choice for molecular diagnostic controls and panels for infectious disease testing,” said Shawn R. Smith, President and CEO of ZeptoMetrix. “Major molecular assay and platform manufacturers, as well as providers of proficiency testing services, count on ZeptoMetrix to ensure that complementary controls and verification materials are developed in the effort to ensure optimal utilization of their assays in the field. The Explify Platform, utilizing a database of over 50,000 microorganisms and over 3,000 infectious pathogens to identify and characterize microorganisms in an unbiased fashion, will be invaluable to us in meeting our clients’ needs for enhanced confidence and biological traceability in the quality controls, reference strains, and proficiency testing materials that we provide.”
“This agreement with ZeptoMetrix announced today is an example of how IDbyDNA’s Explify Platform can support leaders in the field of biological assay development to enhance their capability to deliver highly accurate results,” said IDbyDNA’s CEO, Guochun Liao, Ph.D. “We are constantly updating our databases to ensure we remain at the forefront of metagenomics-based identification of viruses, bacteria, fungi and parasites. We look forward to supporting ZeptoMetrix in delivering easy-to-use, non-infectious, whole organism QC products that provide accurate and consistent results.”
As part of the agreement, IDbyDNA will perform next generation sequencing (RNA and/or DNA) and data analysis using the Explify Platform on viral strains and bacterial isolates provided by ZeptoMetrix. IDbyDNA will provide ZeptoMetrix with identification, genotyping information, and genome sequences of reference strains and will assess the biological purity of these materials.
The Explify Platform simultaneously profiles tens of thousands of microorganisms and pathogens in any sample to deliver actionable information to healthcare providers. This turn-key solution enables clinical laboratories to offer NGS-based metagenomics testing for infectious disease. From sample preparation to report delivery, the Explify Platform manages laboratory workflow, analyzes metagenomics data, and provides applications for clinical review, quality control and reporting. The Explify Platform offers clinical laboratories a streamlined path to offering unbiased, NGS-based Infectious Disease tests that are more comprehensive, and more accurate than conventional tests. Explify metagenomics analysis is a proprietary DNA search engine that analyzes tens of millions of Next-Generation Sequencing reads within minutes to enable the detection of tens of thousands of microorganisms. The proprietary Explify database includes millions of curated DNA and RNA reference sequences and can identify more than 50,000 microorganisms and over 3,000 known common and rare pathogens.
ZeptoMetrix Corporation (ZMC) is a renowned industry leader and innovator identified with quality, reliability and trusted products and services for infectious disease diagnostic development. ZeptoMetrix is a fully integrated biotechnology company whose offerings support all phases of research & development, validation, manufacturing and commercialization of molecular diagnostic assays. Founded in 1999, ZeptoMetrix is headquartered in Buffalo, NY with additional facilities in Franklin, Massachusetts.
IDbyDNA has developed transformative metagenomics technology to simultaneously profile tens of thousands of microorganisms and pathogens in any sample. Our turn-key Explify Platform easily integrates into medical laboratories to deliver actionable information to healthcare providers. Working with our global partners, we are setting the standard for the identification and understanding of microorganisms and their role in human health. www.idbydna.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20190514005081/en/
CONTACT: IDbyDNA media contact
Shai Biran, Ph.D.
ZeptoMetrix media contact
Michael Hershfield, VP Sales & Marketing
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA UTAH
INDUSTRY KEYWORD: TECHNOLOGY SOFTWARE HEALTH BIOTECHNOLOGY CLINICAL TRIALS INFECTIOUS DISEASES PHARMACEUTICAL
Copyright Business Wire 2019.
PUB: 05/14/2019 08:30 AM/DISC: 05/14/2019 08:31 AM